Preclinical Studies of Stem Cell Therapy for Heart Disease.
Preclinical Studies of Stem Cell Therapy for Heart Disease.
复制标题
DOI：
10.1161/circresaha.117.312486
复制
发表时间：
2018-03-30
影响因子：
20.1
通讯作者：
Hare JM
中科院分区：
文献类型：
--
作者：
Tompkins BA;Balkan W;Winkler J;Gyöngyösi M;Goliasch G;Fernández-Avilés F;Hare JM
心血管综合征再生疗法跨国联盟 (TACTICS) 最近的科学声明概述了与心力衰竭干细胞治疗临床前和临床研究相关的许多挑战，并为推动该领域的发展提供了一系列指南和建议。作为本系列的一部分，我们在此讨论旨在推进 CVD 干细胞疗法的临床前研究的作用。这项研究的质量在过去 10-15 年中有所提高，总体表明细胞疗法可促进心脏修复。然而，许多问题仍然存在，包括无法提供完全的心脏恢复。最近的研究质疑完整细胞的必要性，表明利用细胞释放的物质是解决方案。在这里，我们描述了基于细胞的缓解 CVD 方法的重要突破和当前方向。
The recent scientific statement of the transnational alliance for regenerative therapies in cardiovascular syndromes (TACTICS) provided an overview of the many challenges associated with pre-clinical and clinical studies of stem cell therapy for HF and are providing a series of guidelines and recommendations for moving this field forward. As part of this series, here we discuss the role of pre-clinical studies designed to advance stem cell therapies for CVD. The quality of this research has improved over the last 10–15 years and overall indicates that cell therapy promotes cardiac repair. However, many issues remain, including inability to provide complete cardiac recovery. Recent studies question the need for intact cells suggesting that harnessing what the cells release is the solution. Here we describe important breakthroughs and current directions in a cell-based approach to alleviating CVD.